NeuroSense Reports New Data: Statistically Significant Clinical Efficacy in Phase 2b ALS Trial streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
CAMBRIDGE - NeuroSense Therapeutics Ltd. , a company developing treatments for severe neurodegenerative diseases, today reported that it met its primary safety and tolerability endpoints and.
NeuroSense Therapeutics Ltd. (NRSN) announced Tuesday that it met its primary safety and tolerability endpoints and achieved secondary clinical efficacy endpoints in the top-line results of its 6-month, randomized, placebo-controlled, double-blind segment the Company's Phase 2b amyotrophic lateral sclerosis (ALS) trial of PrimeC (PARADIGM).
Neurosense Therapeutics (NRSN) Phase 2b ALS Trial Achieves Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for neurodegenerative diseases, today announced it.